#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Blunted Frontostriatal BOLD Signals Predict Stimulant and Marijuana Use Background Occasional, recreational stimulant (amphetamine and cocaine) use is an important public health problem among young adults because 16% of those who experiment develop stimulant use disorder (SUD).
1-1	0-7	Blunted	_
1-2	8-22	Frontostriatal	_
1-3	23-27	BOLD	_
1-4	28-35	Signals	_
1-5	36-43	Predict	_
1-6	44-53	Stimulant	_
1-7	54-57	and	_
1-8	58-67	Marijuana	_
1-9	68-71	Use	_
1-10	72-82	Background	_
1-11	83-93	Occasional	_
1-12	94-95	,	_
1-13	96-108	recreational	_
1-14	109-118	stimulant	_
1-15	119-120	(	_
1-16	121-132	amphetamine	_
1-17	133-136	and	_
1-18	137-144	cocaine	_
1-19	145-146	)	_
1-20	147-150	use	_
1-21	151-153	is	_
1-22	154-156	an	_
1-23	157-166	important	_
1-24	167-173	public	_
1-25	174-180	health	_
1-26	181-188	problem	_
1-27	189-194	among	_
1-28	195-200	young	_
1-29	201-207	adults	_
1-30	208-215	because	_
1-31	216-218	16	_
1-32	219-220	%	_
1-33	221-223	of	_
1-34	224-229	those	_
1-35	230-233	who	_
1-36	234-244	experiment	_
1-37	245-252	develop	_
1-38	253-262	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#AutisticDisorder
1-39	263-266	use	http://maven.renci.org/NeuroBridge/neurobridge#AutisticDisorder
1-40	267-275	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutisticDisorder
1-41	276-277	(	http://maven.renci.org/NeuroBridge/neurobridge#AutisticDisorder
1-42	278-281	SUD	http://maven.renci.org/NeuroBridge/neurobridge#AutisticDisorder
1-43	282-283	)	http://maven.renci.org/NeuroBridge/neurobridge#AutisticDisorder
1-44	284-285	.	_

Text=This study aimed to determine whether behavioral and/or neural processing measures can forecast the transition from occasional to problematic stimulant use.
2-1	286-290	This	_
2-2	291-296	study	_
2-3	297-302	aimed	_
2-4	303-305	to	_
2-5	306-315	determine	_
2-6	316-323	whether	_
2-7	324-334	behavioral	_
2-8	335-341	and/or	_
2-9	342-348	neural	_
2-10	349-359	processing	_
2-11	360-368	measures	_
2-12	369-372	can	_
2-13	373-381	forecast	_
2-14	382-385	the	_
2-15	386-396	transition	_
2-16	397-401	from	_
2-17	402-412	occasional	_
2-18	413-415	to	_
2-19	416-427	problematic	_
2-20	428-437	stimulant	_
2-21	438-441	use	_
2-22	442-443	.	_

Text=Methods Occasional stimulant users (OSU) completed a Risky Gains Task during functional magnetic resonance imaging and were followed up three years later.
3-1	444-451	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
3-2	452-462	Occasional	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
3-3	463-472	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
3-4	473-478	users	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
3-5	479-480	(	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
3-6	481-484	OSU	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
3-7	485-486	)	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
3-8	487-496	completed	_
3-9	497-498	a	_
3-10	499-504	Risky	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
3-11	505-510	Gains	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
3-12	511-515	Task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
3-13	516-522	during	_
3-14	523-533	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-15	534-542	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-16	543-552	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-17	553-560	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-18	561-564	and	_
3-19	565-569	were	_
3-20	570-578	followed	_
3-21	579-581	up	_
3-22	582-587	three	_
3-23	588-593	years	_
3-24	594-599	later	_
3-25	600-601	.	_

Text=Categorical analyses tested whether blood oxygen level dependent (BOLD) responses differentiated OSU who became problem stimulant users (PSU; n=35) from those who desisted stimulant use (DSU; n=75) at follow-up.
4-1	602-613	Categorical	_
4-2	614-622	analyses	_
4-3	623-629	tested	_
4-4	630-637	whether	_
4-5	638-643	blood	_
4-6	644-650	oxygen	_
4-7	651-656	level	_
4-8	657-666	dependent	_
4-9	667-668	(	_
4-10	669-673	BOLD	_
4-11	674-675	)	_
4-12	676-685	responses	_
4-13	686-700	differentiated	_
4-14	701-704	OSU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-15	705-708	who	_
4-16	709-715	became	_
4-17	716-723	problem	_
4-18	724-733	stimulant	_
4-19	734-739	users	_
4-20	740-741	(	_
4-21	742-745	PSU	_
4-22	746-747	;	_
4-23	748-752	n=35	_
4-24	753-754	)	_
4-25	755-759	from	_
4-26	760-765	those	_
4-27	766-769	who	_
4-28	770-778	desisted	_
4-29	779-788	stimulant	_
4-30	789-792	use	_
4-31	793-794	(	_
4-32	795-798	DSU	_
4-33	799-800	;	_
4-34	801-805	n=75	_
4-35	806-807	)	_
4-36	808-810	at	_
4-37	811-820	follow-up	_
4-38	821-822	.	_

Text=Dimensional analyses (regardless of PSU or DSU membership; n=144) tested whether BOLD responses predicted baseline and follow-up stimulant and marijuana use.
5-1	823-834	Dimensional	_
5-2	835-843	analyses	_
5-3	844-845	(	_
5-4	846-856	regardless	_
5-5	857-859	of	_
5-6	860-863	PSU	_
5-7	864-866	or	_
5-8	867-870	DSU	_
5-9	871-881	membership	_
5-10	882-883	;	_
5-11	884-889	n=144	_
5-12	890-891	)	_
5-13	892-898	tested	_
5-14	899-906	whether	_
5-15	907-911	BOLD	_
5-16	912-921	responses	_
5-17	922-931	predicted	_
5-18	932-940	baseline	_
5-19	941-944	and	_
5-20	945-954	follow-up	_
5-21	955-964	stimulant	_
5-22	965-968	and	_
5-23	969-978	marijuana	_
5-24	979-982	use	_
5-25	983-984	.	_

Text=Results Categorical results indicated that relative to DSU, PSU: 1) made riskier decisions after winning feedback; 2) exhibited lower frontal, insular, and striatal BOLD responses to win/loss feedback after making risky decisions; 3) displayed lower thalamic but greater temporo-occipital BOLD responses to risky losses than wins.
6-1	985-992	Results	_
6-2	993-1004	Categorical	_
6-3	1005-1012	results	_
6-4	1013-1022	indicated	_
6-5	1023-1027	that	_
6-6	1028-1036	relative	_
6-7	1037-1039	to	_
6-8	1040-1043	DSU	http://maven.renci.org/NeuroBridge/neurobridge#BloodSubstanceMeasurement
6-9	1044-1045	,	_
6-10	1046-1049	PSU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-11	1050-1051	:	_
6-12	1052-1053	1	_
6-13	1054-1055	)	_
6-14	1056-1060	made	_
6-15	1061-1068	riskier	_
6-16	1069-1078	decisions	_
6-17	1079-1084	after	_
6-18	1085-1092	winning	_
6-19	1093-1101	feedback	_
6-20	1102-1103	;	_
6-21	1104-1105	2	_
6-22	1106-1107	)	_
6-23	1108-1117	exhibited	_
6-24	1118-1123	lower	_
6-25	1124-1131	frontal	_
6-26	1132-1133	,	_
6-27	1134-1141	insular	_
6-28	1142-1143	,	_
6-29	1144-1147	and	_
6-30	1148-1156	striatal	_
6-31	1157-1161	BOLD	_
6-32	1162-1171	responses	_
6-33	1172-1174	to	_
6-34	1175-1183	win/loss	_
6-35	1184-1192	feedback	_
6-36	1193-1198	after	_
6-37	1199-1205	making	_
6-38	1206-1211	risky	_
6-39	1212-1221	decisions	_
6-40	1222-1223	;	_
6-41	1224-1225	3	_
6-42	1226-1227	)	_
6-43	1228-1237	displayed	_
6-44	1238-1243	lower	_
6-45	1244-1252	thalamic	_
6-46	1253-1256	but	_
6-47	1257-1264	greater	_
6-48	1265-1282	temporo-occipital	_
6-49	1283-1287	BOLD	_
6-50	1288-1297	responses	_
6-51	1298-1300	to	_
6-52	1301-1306	risky	_
6-53	1307-1313	losses	_
6-54	1314-1318	than	_
6-55	1319-1323	wins	_
6-56	1324-1325	.	_

Text=In comparison, dimensional results indicated that lower BOLD signal to risky than safe choices in frontal, striatal, and additional regions predicted greater marijuana use at follow-up.
7-1	1326-1328	In	_
7-2	1329-1339	comparison	_
7-3	1340-1341	,	_
7-4	1342-1353	dimensional	_
7-5	1354-1361	results	_
7-6	1362-1371	indicated	_
7-7	1372-1376	that	_
7-8	1377-1382	lower	_
7-9	1383-1387	BOLD	_
7-10	1388-1394	signal	_
7-11	1395-1397	to	_
7-12	1398-1403	risky	_
7-13	1404-1408	than	_
7-14	1409-1413	safe	_
7-15	1414-1421	choices	_
7-16	1422-1424	in	_
7-17	1425-1432	frontal	_
7-18	1433-1434	,	_
7-19	1435-1443	striatal	_
7-20	1444-1445	,	_
7-21	1446-1449	and	_
7-22	1450-1460	additional	_
7-23	1461-1468	regions	_
7-24	1469-1478	predicted	_
7-25	1479-1486	greater	_
7-26	1487-1496	marijuana	_
7-27	1497-1500	use	_
7-28	1501-1503	at	_
7-29	1504-1513	follow-up	_
7-30	1514-1515	.	_

Text=Conclusions Taken together, blunted frontostriatal signals during risky choices may quantify vulnerability to future marijuana consumption, whereas blunted frontostriatal signals to risky outcomes mark risk for future SUD.
8-1	1516-1527	Conclusions	_
8-2	1528-1533	Taken	_
8-3	1534-1542	together	_
8-4	1543-1544	,	_
8-5	1545-1552	blunted	_
8-6	1553-1567	frontostriatal	_
8-7	1568-1575	signals	_
8-8	1576-1582	during	_
8-9	1583-1588	risky	_
8-10	1589-1596	choices	_
8-11	1597-1600	may	_
8-12	1601-1609	quantify	_
8-13	1610-1623	vulnerability	_
8-14	1624-1626	to	_
8-15	1627-1633	future	_
8-16	1634-1643	marijuana	_
8-17	1644-1655	consumption	_
8-18	1656-1657	,	_
8-19	1658-1665	whereas	_
8-20	1666-1673	blunted	_
8-21	1674-1688	frontostriatal	_
8-22	1689-1696	signals	_
8-23	1697-1699	to	_
8-24	1700-1705	risky	_
8-25	1706-1714	outcomes	_
8-26	1715-1719	mark	_
8-27	1720-1724	risk	_
8-28	1725-1728	for	_
8-29	1729-1735	future	_
8-30	1736-1739	SUD	_
8-31	1740-1741	.	_

Text=These behavioral and neural processing measures may prove useful for identifying ultra-high risk individuals prior to onset of problem drug use.
9-1	1742-1747	These	_
9-2	1748-1758	behavioral	_
9-3	1759-1762	and	_
9-4	1763-1769	neural	_
9-5	1770-1780	processing	_
9-6	1781-1789	measures	_
9-7	1790-1793	may	_
9-8	1794-1799	prove	_
9-9	1800-1806	useful	_
9-10	1807-1810	for	_
9-11	1811-1822	identifying	_
9-12	1823-1833	ultra-high	_
9-13	1834-1838	risk	_
9-14	1839-1850	individuals	_
9-15	1851-1856	prior	_
9-16	1857-1859	to	_
9-17	1860-1865	onset	_
9-18	1866-1868	of	_
9-19	1869-1876	problem	_
9-20	1877-1881	drug	_
9-21	1882-1885	use	_
9-22	1886-1887	.	_

Text=Methods and Materials Participants The University of California, San Diego Human Subjects Review Board approved the study protocol.
10-1	1888-1895	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1896-1899	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1900-1909	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1910-1922	Participants	_
10-5	1923-1926	The	_
10-6	1927-1937	University	_
10-7	1938-1940	of	_
10-8	1941-1951	California	_
10-9	1952-1953	,	_
10-10	1954-1957	San	_
10-11	1958-1963	Diego	_
10-12	1964-1969	Human	_
10-13	1970-1978	Subjects	_
10-14	1979-1985	Review	_
10-15	1986-1991	Board	_
10-16	1992-2000	approved	_
10-17	2001-2004	the	_
10-18	2005-2010	study	_
10-19	2011-2019	protocol	_
10-20	2020-2021	.	_

Text=Participants were recruited through newspapers, internet ads and fliers mailed to college students.
11-1	2022-2034	Participants	_
11-2	2035-2039	were	_
11-3	2040-2049	recruited	_
11-4	2050-2057	through	_
11-5	2058-2068	newspapers	_
11-6	2069-2070	,	_
11-7	2071-2079	internet	_
11-8	2080-2083	ads	_
11-9	2084-2087	and	_
11-10	2088-2094	fliers	_
11-11	2095-2101	mailed	_
11-12	2102-2104	to	_
11-13	2105-2112	college	_
11-14	2113-2121	students	_
11-15	2122-2123	.	_

Text=Figure 1 demonstrates participant recruitment and categorical/dimensional data analysis protocol.
12-1	2124-2130	Figure	_
12-2	2131-2132	1	_
12-3	2133-2145	demonstrates	_
12-4	2146-2157	participant	_
12-5	2158-2169	recruitment	_
12-6	2170-2173	and	_
12-7	2174-2197	categorical/dimensional	_
12-8	2198-2202	data	_
12-9	2203-2211	analysis	_
12-10	2212-2220	protocol	_
12-11	2221-2222	.	_

Text=A total of 1025 individuals were phone-screened and 184 OSU meeting study criteria provided written informed consent to participate.
13-1	2223-2224	A	_
13-2	2225-2230	total	_
13-3	2231-2233	of	_
13-4	2234-2238	1025	_
13-5	2239-2250	individuals	_
13-6	2251-2255	were	_
13-7	2256-2270	phone-screened	_
13-8	2271-2274	and	_
13-9	2275-2278	184	_
13-10	2279-2282	OSU	_
13-11	2283-2290	meeting	_
13-12	2291-2296	study	_
13-13	2297-2305	criteria	_
13-14	2306-2314	provided	_
13-15	2315-2322	written	_
13-16	2323-2331	informed	_
13-17	2332-2339	consent	_
13-18	2340-2342	to	_
13-19	2343-2354	participate	_
13-20	2355-2356	.	_

Text=OSU inclusionary criteria were: 1) within the last 6 months, 2+ separate occasions cocaine or prescription amphetamines (e.g.
14-1	2357-2360	OSU	_
14-2	2361-2373	inclusionary	_
14-3	2374-2382	criteria	_
14-4	2383-2387	were	_
14-5	2388-2389	:	_
14-6	2390-2391	1	_
14-7	2392-2393	)	_
14-8	2394-2400	within	_
14-9	2401-2404	the	_
14-10	2405-2409	last	_
14-11	2410-2411	6	_
14-12	2412-2418	months	_
14-13	2419-2420	,	_
14-14	2421-2423	2+	_
14-15	2424-2432	separate	_
14-16	2433-2442	occasions	_
14-17	2443-2450	cocaine	_
14-18	2451-2453	or	_
14-19	2454-2466	prescription	_
14-20	2467-2479	amphetamines	_
14-21	2480-2481	(	_
14-22	2482-2485	e.g	_
14-23	2486-2487	.	_

Text=methylphenidate (Adderall), dextroamphetamine (Ritalin) used without a prescribed purpose; 2) no lifetime stimulant dependence; 3) no lifetime stimulant use for medical reasons; and 4) no drug treatment interest.
15-1	2488-2503	methylphenidate	_
15-2	2504-2505	(	_
15-3	2506-2514	Adderall	_
15-4	2515-2516	)	_
15-5	2517-2518	,	_
15-6	2519-2536	dextroamphetamine	_
15-7	2537-2538	(	_
15-8	2539-2546	Ritalin	_
15-9	2547-2548	)	_
15-10	2549-2553	used	_
15-11	2554-2561	without	_
15-12	2562-2563	a	_
15-13	2564-2574	prescribed	_
15-14	2575-2582	purpose	_
15-15	2583-2584	;	_
15-16	2585-2586	2	_
15-17	2587-2588	)	_
15-18	2589-2591	no	_
15-19	2592-2600	lifetime	_
15-20	2601-2610	stimulant	_
15-21	2611-2621	dependence	_
15-22	2622-2623	;	_
15-23	2624-2625	3	_
15-24	2626-2627	)	_
15-25	2628-2630	no	_
15-26	2631-2639	lifetime	_
15-27	2640-2649	stimulant	_
15-28	2650-2653	use	_
15-29	2654-2657	for	_
15-30	2658-2665	medical	_
15-31	2666-2673	reasons	_
15-32	2674-2675	;	_
15-33	2676-2679	and	_
15-34	2680-2681	4	_
15-35	2682-2683	)	_
15-36	2684-2686	no	_
15-37	2687-2691	drug	_
15-38	2692-2701	treatment	_
15-39	2702-2710	interest	_
15-40	2711-2712	.	_

Text=Participants completed three sessions: 1) a baseline diagnostic interview to determine lifetime psychiatric diagnoses and current drug use patterns (n=184); 2) a neuroimaging session completing the RGT (n=161), and 3) a follow-up interview session three years later to determine changes in drug use and clinical diagnoses (n=144).
16-1	2713-2725	Participants	_
16-2	2726-2735	completed	_
16-3	2736-2741	three	_
16-4	2742-2750	sessions	_
16-5	2751-2752	:	_
16-6	2753-2754	1	_
16-7	2755-2756	)	_
16-8	2757-2758	a	_
16-9	2759-2767	baseline	_
16-10	2768-2778	diagnostic	_
16-11	2779-2788	interview	_
16-12	2789-2791	to	_
16-13	2792-2801	determine	_
16-14	2802-2810	lifetime	_
16-15	2811-2822	psychiatric	_
16-16	2823-2832	diagnoses	_
16-17	2833-2836	and	_
16-18	2837-2844	current	_
16-19	2845-2849	drug	_
16-20	2850-2853	use	_
16-21	2854-2862	patterns	_
16-22	2863-2864	(	_
16-23	2865-2870	n=184	_
16-24	2871-2872	)	_
16-25	2873-2874	;	_
16-26	2875-2876	2	_
16-27	2877-2878	)	_
16-28	2879-2880	a	_
16-29	2881-2893	neuroimaging	_
16-30	2894-2901	session	_
16-31	2902-2912	completing	_
16-32	2913-2916	the	_
16-33	2917-2920	RGT	_
16-34	2921-2922	(	_
16-35	2923-2928	n=161	_
16-36	2929-2930	)	_
16-37	2931-2932	,	_
16-38	2933-2936	and	_
16-39	2937-2938	3	_
16-40	2939-2940	)	_
16-41	2941-2942	a	_
16-42	2943-2952	follow-up	_
16-43	2953-2962	interview	_
16-44	2963-2970	session	_
16-45	2971-2976	three	_
16-46	2977-2982	years	_
16-47	2983-2988	later	_
16-48	2989-2991	to	_
16-49	2992-3001	determine	_
16-50	3002-3009	changes	_
16-51	3010-3012	in	_
16-52	3013-3017	drug	_
16-53	3018-3021	use	_
16-54	3022-3025	and	_
16-55	3026-3034	clinical	_
16-56	3035-3044	diagnoses	_
16-57	3045-3046	(	_
16-58	3047-3052	n=144	_
16-59	3053-3054	)	_
16-60	3055-3056	.	_

Text=The present study includes data from OSU who completed all three sessions (n=144).
17-1	3057-3060	The	_
17-2	3061-3068	present	_
17-3	3069-3074	study	_
17-4	3075-3083	includes	_
17-5	3084-3088	data	_
17-6	3089-3093	from	_
17-7	3094-3097	OSU	_
17-8	3098-3101	who	_
17-9	3102-3111	completed	_
17-10	3112-3115	all	_
17-11	3116-3121	three	_
17-12	3122-3130	sessions	_
17-13	3131-3132	(	_
17-14	3133-3138	n=144	_
17-15	3139-3140	)	_
17-16	3141-3142	.	_

Text=No OSU reported using methamphetamines at baseline; all baseline stimulant use was of cocaine and prescription stimulants.
18-1	3143-3145	No	_
18-2	3146-3149	OSU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-3	3150-3158	reported	_
18-4	3159-3164	using	_
18-5	3165-3181	methamphetamines	_
18-6	3182-3184	at	_
18-7	3185-3193	baseline	_
18-8	3194-3195	;	_
18-9	3196-3199	all	_
18-10	3200-3208	baseline	_
18-11	3209-3218	stimulant	_
18-12	3219-3222	use	_
18-13	3223-3226	was	_
18-14	3227-3229	of	_
18-15	3230-3237	cocaine	_
18-16	3238-3241	and	_
18-17	3242-3254	prescription	_
18-18	3255-3265	stimulants	_
18-19	3266-3267	.	_

Text=Baseline Session Participants were screened for lifetime DSM-IV Axis I diagnoses (including attention deficit hyperactivity disorder (ADHD), and substance abuse/dependence) and Axis II antisocial personality disorder by the Semi-Structured Assessment for the Genetics of Alcoholism II, and administered the Wechsler Test of Adult Reading, a verbal intelligence measure (IQ).
19-1	3268-3276	Baseline	_
19-2	3277-3284	Session	_
19-3	3285-3297	Participants	_
19-4	3298-3302	were	_
19-5	3303-3311	screened	_
19-6	3312-3315	for	_
19-7	3316-3324	lifetime	_
19-8	3325-3331	DSM-IV	_
19-9	3332-3336	Axis	_
19-10	3337-3338	I	_
19-11	3339-3348	diagnoses	_
19-12	3349-3350	(	_
19-13	3351-3360	including	_
19-14	3361-3370	attention	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
19-15	3371-3378	deficit	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
19-16	3379-3392	hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
19-17	3393-3401	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
19-18	3402-3403	(	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
19-19	3404-3408	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
19-20	3409-3410	)	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
19-21	3411-3412	,	_
19-22	3413-3416	and	_
19-23	3417-3426	substance	_
19-24	3427-3443	abuse/dependence	_
19-25	3444-3445	)	_
19-26	3446-3449	and	_
19-27	3450-3454	Axis	_
19-28	3455-3457	II	_
19-29	3458-3468	antisocial	_
19-30	3469-3480	personality	_
19-31	3481-3489	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
19-32	3490-3492	by	_
19-33	3493-3496	the	_
19-34	3497-3512	Semi-Structured	_
19-35	3513-3523	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-36	3524-3527	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-37	3528-3531	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
19-38	3532-3540	Genetics	_
19-39	3541-3543	of	_
19-40	3544-3554	Alcoholism	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
19-41	3555-3557	II	_
19-42	3558-3559	,	_
19-43	3560-3563	and	_
19-44	3564-3576	administered	_
19-45	3577-3580	the	_
19-46	3581-3589	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
19-47	3590-3594	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
19-48	3595-3597	of	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
19-49	3598-3603	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
19-50	3604-3611	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
19-51	3612-3613	,	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
19-52	3614-3615	a	_
19-53	3616-3622	verbal	http://maven.renci.org/NeuroBridge/neurobridge#TestofNonverbalIntelligence
19-54	3623-3635	intelligence	http://maven.renci.org/NeuroBridge/neurobridge#TestofNonverbalIntelligence
19-55	3636-3643	measure	http://maven.renci.org/NeuroBridge/neurobridge#TestofNonverbalIntelligence
19-56	3644-3645	(	http://maven.renci.org/NeuroBridge/neurobridge#TestofNonverbalIntelligence
19-57	3646-3648	IQ	http://maven.renci.org/NeuroBridge/neurobridge#TestofNonverbalIntelligence
19-58	3649-3650	)	http://maven.renci.org/NeuroBridge/neurobridge#TestofNonverbalIntelligence
19-59	3651-3652	.	_

Text=Exclusion criteria is outlined in Stewart et al.
20-1	3653-3662	Exclusion	_
20-2	3663-3671	criteria	_
20-3	3672-3674	is	_
20-4	3675-3683	outlined	_
20-5	3684-3686	in	_
20-6	3687-3694	Stewart	_
20-7	3695-3697	et	_
20-8	3698-3700	al	_
20-9	3701-3702	.	_

Text=and is included as supplemental information.
21-1	3703-3706	and	_
21-2	3707-3709	is	_
21-3	3710-3718	included	_
21-4	3719-3721	as	_
21-5	3722-3734	supplemental	_
21-6	3735-3746	information	_
21-7	3747-3748	.	_

Text=Subjects completed a baseline urine toxicology screen and were excluded if they tested positive for stimulants (thereby avoiding confounding effects from recent use).
22-1	3749-3757	Subjects	_
22-2	3758-3767	completed	_
22-3	3768-3769	a	_
22-4	3770-3778	baseline	_
22-5	3779-3784	urine	_
22-6	3785-3795	toxicology	_
22-7	3796-3802	screen	_
22-8	3803-3806	and	_
22-9	3807-3811	were	_
22-10	3812-3820	excluded	_
22-11	3821-3823	if	_
22-12	3824-3828	they	_
22-13	3829-3835	tested	_
22-14	3836-3844	positive	_
22-15	3845-3848	for	_
22-16	3849-3859	stimulants	_
22-17	3860-3861	(	_
22-18	3862-3869	thereby	_
22-19	3870-3878	avoiding	_
22-20	3879-3890	confounding	_
22-21	3891-3898	effects	_
22-22	3899-3903	from	_
22-23	3904-3910	recent	_
22-24	3911-3914	use	_
22-25	3915-3916	)	_
22-26	3917-3918	.	_

Text=Testing positive for cannabis was not exclusionary, as its urine presence may last up to 6 weeks.
23-1	3919-3926	Testing	_
23-2	3927-3935	positive	_
23-3	3936-3939	for	_
23-4	3940-3948	cannabis	_
23-5	3949-3952	was	_
23-6	3953-3956	not	_
23-7	3957-3969	exclusionary	_
23-8	3970-3971	,	_
23-9	3972-3974	as	_
23-10	3975-3978	its	_
23-11	3979-3984	urine	_
23-12	3985-3993	presence	_
23-13	3994-3997	may	_
23-14	3998-4002	last	_
23-15	4003-4005	up	_
23-16	4006-4008	to	_
23-17	4009-4010	6	_
23-18	4011-4016	weeks	_
23-19	4017-4018	.	_

Text=Risky Gains Task (RGT) The RGT (illustrated in Figure 2) has been previously described by our experimental group.
24-1	4019-4024	Risky	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
24-2	4025-4030	Gains	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
24-3	4031-4035	Task	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
24-4	4036-4037	(	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
24-5	4038-4041	RGT	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
24-6	4042-4043	)	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask
24-7	4044-4047	The	_
24-8	4048-4051	RGT	_
24-9	4052-4053	(	_
24-10	4054-4065	illustrated	_
24-11	4066-4068	in	_
24-12	4069-4075	Figure	_
24-13	4076-4077	2	_
24-14	4078-4079	)	_
24-15	4080-4083	has	_
24-16	4084-4088	been	_
24-17	4089-4099	previously	_
24-18	4100-4109	described	_
24-19	4110-4112	by	_
24-20	4113-4116	our	_
24-21	4117-4129	experimental	_
24-22	4130-4135	group	_
24-23	4136-4137	.	_

Text=On each trial, participants were shown the numbers 20, 40, and 80 in increasing order, which represented the number of cents to be added to their total.
25-1	4138-4140	On	_
25-2	4141-4145	each	_
25-3	4146-4151	trial	_
25-4	4152-4153	,	_
25-5	4154-4166	participants	_
25-6	4167-4171	were	_
25-7	4172-4177	shown	_
25-8	4178-4181	the	_
25-9	4182-4189	numbers	_
25-10	4190-4192	20	_
25-11	4193-4194	,	_
25-12	4195-4197	40	_
25-13	4198-4199	,	_
25-14	4200-4203	and	_
25-15	4204-4206	80	_
25-16	4207-4209	in	_
25-17	4210-4220	increasing	_
25-18	4221-4226	order	_
25-19	4227-4228	,	_
25-20	4229-4234	which	_
25-21	4235-4246	represented	_
25-22	4247-4250	the	_
25-23	4251-4257	number	_
25-24	4258-4260	of	_
25-25	4261-4266	cents	_
25-26	4267-4269	to	_
25-27	4270-4272	be	_
25-28	4273-4278	added	_
25-29	4279-4281	to	_
25-30	4282-4287	their	_
25-31	4288-4293	total	_
25-32	4294-4295	.	_

Text=Participants were informed that 20 was always the “ safe option ” but that they had the option to wait 1s to receive 40 cents or wait an additional second to receive 80 cents.
26-1	4296-4308	Participants	_
26-2	4309-4313	were	_
26-3	4314-4322	informed	_
26-4	4323-4327	that	_
26-5	4328-4330	20	_
26-6	4331-4334	was	_
26-7	4335-4341	always	_
26-8	4342-4345	the	_
26-9	4346-4347	“	_
26-10	4348-4352	safe	_
26-11	4353-4359	option	_
26-12	4360-4361	”	_
26-13	4362-4365	but	_
26-14	4366-4370	that	_
26-15	4371-4375	they	_
26-16	4376-4379	had	_
26-17	4380-4383	the	_
26-18	4384-4390	option	_
26-19	4391-4393	to	_
26-20	4394-4398	wait	_
26-21	4399-4401	1s	_
26-22	4402-4404	to	_
26-23	4405-4412	receive	_
26-24	4413-4415	40	_
26-25	4416-4421	cents	_
26-26	4422-4424	or	_
26-27	4425-4429	wait	_
26-28	4430-4432	an	_
26-29	4433-4443	additional	_
26-30	4444-4450	second	_
26-31	4451-4453	to	_
26-32	4454-4461	receive	_
26-33	4462-4464	80	_
26-34	4465-4470	cents	_
26-35	4471-4472	.	_

Text=They were also informed of the potential that 40 or 80 would appear in red font, denoting actual losses of money (-40 or -80) from the total score; 40 and 80 were explicitly called “ risky options. ” Unknown to subjects, −40 and −80 outcome frequencies were predefined so that the final gain was identical regardless of whether they selected 20, 40, or 80 cents.
27-1	4473-4477	They	_
27-2	4478-4482	were	_
27-3	4483-4487	also	_
27-4	4488-4496	informed	_
27-5	4497-4499	of	_
27-6	4500-4503	the	_
27-7	4504-4513	potential	_
27-8	4514-4518	that	_
27-9	4519-4521	40	_
27-10	4522-4524	or	_
27-11	4525-4527	80	_
27-12	4528-4533	would	_
27-13	4534-4540	appear	_
27-14	4541-4543	in	_
27-15	4544-4547	red	_
27-16	4548-4552	font	_
27-17	4553-4554	,	_
27-18	4555-4563	denoting	_
27-19	4564-4570	actual	_
27-20	4571-4577	losses	_
27-21	4578-4580	of	_
27-22	4581-4586	money	_
27-23	4587-4588	(	_
27-24	4589-4592	-40	_
27-25	4593-4595	or	_
27-26	4596-4599	-80	_
27-27	4600-4601	)	_
27-28	4602-4606	from	_
27-29	4607-4610	the	_
27-30	4611-4616	total	_
27-31	4617-4622	score	_
27-32	4623-4624	;	_
27-33	4625-4627	40	_
27-34	4628-4631	and	_
27-35	4632-4634	80	_
27-36	4635-4639	were	_
27-37	4640-4650	explicitly	_
27-38	4651-4657	called	_
27-39	4658-4659	“	_
27-40	4660-4665	risky	_
27-41	4666-4674	options.	_
27-42	4675-4676	”	_
27-43	4677-4684	Unknown	_
27-44	4685-4687	to	_
27-45	4688-4696	subjects	_
27-46	4697-4698	,	_
27-47	4699-4702	−40	_
27-48	4703-4706	and	_
27-49	4707-4710	−80	_
27-50	4711-4718	outcome	_
27-51	4719-4730	frequencies	_
27-52	4731-4735	were	_
27-53	4736-4746	predefined	_
27-54	4747-4749	so	_
27-55	4750-4754	that	_
27-56	4755-4758	the	_
27-57	4759-4764	final	_
27-58	4765-4769	gain	_
27-59	4770-4773	was	_
27-60	4774-4783	identical	_
27-61	4784-4794	regardless	_
27-62	4795-4797	of	_
27-63	4798-4805	whether	_
27-64	4806-4810	they	_
27-65	4811-4819	selected	_
27-66	4820-4822	20	_
27-67	4823-4824	,	_
27-68	4825-4827	40	_
27-69	4828-4829	,	_
27-70	4830-4832	or	_
27-71	4833-4835	80	_
27-72	4836-4841	cents	_
27-73	4842-4843	.	_

Text=That is, there was no actual advantage of selecting risky compared to safe options.
28-1	4844-4848	That	_
28-2	4849-4851	is	_
28-3	4852-4853	,	_
28-4	4854-4859	there	_
28-5	4860-4863	was	_
28-6	4864-4866	no	_
28-7	4867-4873	actual	_
28-8	4874-4883	advantage	_
28-9	4884-4886	of	_
28-10	4887-4896	selecting	_
28-11	4897-4902	risky	_
28-12	4903-4911	compared	_
28-13	4912-4914	to	_
28-14	4915-4919	safe	_
28-15	4920-4927	options	_
28-16	4928-4929	.	_

Text=Participants were told that a positive value had to be collected via an index finger button press within a subsequent 1s window.
29-1	4930-4942	Participants	_
29-2	4943-4947	were	_
29-3	4948-4952	told	_
29-4	4953-4957	that	_
29-5	4958-4959	a	_
29-6	4960-4968	positive	_
29-7	4969-4974	value	_
29-8	4975-4978	had	_
29-9	4979-4981	to	_
29-10	4982-4984	be	_
29-11	4985-4994	collected	_
29-12	4995-4998	via	_
29-13	4999-5001	an	_
29-14	5002-5007	index	_
29-15	5008-5014	finger	_
29-16	5015-5021	button	_
29-17	5022-5027	press	_
29-18	5028-5034	within	_
29-19	5035-5036	a	_
29-20	5037-5047	subsequent	_
29-21	5048-5050	1s	_
29-22	5051-5057	window	_
29-23	5058-5059	.	_

Text=A press outside of that timeframe would result in a loss.
30-1	5060-5061	A	_
30-2	5062-5067	press	_
30-3	5068-5075	outside	_
30-4	5076-5078	of	_
30-5	5079-5083	that	_
30-6	5084-5093	timeframe	_
30-7	5094-5099	would	_
30-8	5100-5106	result	_
30-9	5107-5109	in	_
30-10	5110-5111	a	_
30-11	5112-5116	loss	_
30-12	5117-5118	.	_

Text=The 1s length was chosen to allow slow-responding individuals to collect an option.
31-1	5119-5122	The	_
31-2	5123-5125	1s	_
31-3	5126-5132	length	_
31-4	5133-5136	was	_
31-5	5137-5143	chosen	_
31-6	5144-5146	to	_
31-7	5147-5152	allow	_
31-8	5153-5168	slow-responding	_
31-9	5169-5180	individuals	_
31-10	5181-5183	to	_
31-11	5184-5191	collect	_
31-12	5192-5194	an	_
31-13	5195-5201	option	_
31-14	5202-5203	.	_

Text=Auditory and visual feedback (“ yay ” / “ You win ” for wins and “ yuck ” / “ You lose ” for losses) followed each choice.
32-1	5204-5212	Auditory	_
32-2	5213-5216	and	_
32-3	5217-5223	visual	_
32-4	5224-5232	feedback	_
32-5	5233-5234	(	_
32-6	5235-5236	“	_
32-7	5237-5240	yay	_
32-8	5241-5242	”	_
32-9	5243-5244	/	_
32-10	5245-5246	“	_
32-11	5247-5250	You	_
32-12	5251-5254	win	_
32-13	5255-5256	”	_
32-14	5257-5260	for	_
32-15	5261-5265	wins	_
32-16	5266-5269	and	_
32-17	5270-5271	“	_
32-18	5272-5276	yuck	_
32-19	5277-5278	”	_
32-20	5279-5280	/	_
32-21	5281-5282	“	_
32-22	5283-5286	You	_
32-23	5287-5291	lose	_
32-24	5292-5293	”	_
32-25	5294-5297	for	_
32-26	5298-5304	losses	_
32-27	5305-5306	)	_
32-28	5307-5315	followed	_
32-29	5316-5320	each	_
32-30	5321-5327	choice	_
32-31	5328-5329	.	_

Text=Cumulative total (in dollars) was displayed after trial completion to allow performance monitoring.
33-1	5330-5340	Cumulative	_
33-2	5341-5346	total	_
33-3	5347-5348	(	_
33-4	5349-5351	in	_
33-5	5352-5359	dollars	_
33-6	5360-5361	)	_
33-7	5362-5365	was	_
33-8	5366-5375	displayed	_
33-9	5376-5381	after	_
33-10	5382-5387	trial	_
33-11	5388-5398	completion	_
33-12	5399-5401	to	_
33-13	5402-5407	allow	_
33-14	5408-5419	performance	_
33-15	5420-5430	monitoring	_
33-16	5431-5432	.	_

Text=The task consisted of 96 trials lasting 3.5s each.
34-1	5433-5436	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-2	5437-5441	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-3	5442-5451	consisted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-4	5452-5454	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-5	5455-5457	96	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-6	5458-5464	trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-7	5465-5472	lasting	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-8	5473-5477	3.5s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-9	5478-5482	each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-10	5483-5484	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging

Text=Three trial types were presented in a pre-set randomized order: 54 rewarded (+20, +40, +80), 24 punished −40, and 18 punished −80 trials.
35-1	5485-5490	Three	_
35-2	5491-5496	trial	_
35-3	5497-5502	types	_
35-4	5503-5507	were	_
35-5	5508-5517	presented	_
35-6	5518-5520	in	_
35-7	5521-5522	a	_
35-8	5523-5530	pre-set	_
35-9	5531-5541	randomized	_
35-10	5542-5547	order	_
35-11	5548-5549	:	_
35-12	5550-5552	54	_
35-13	5553-5561	rewarded	_
35-14	5562-5563	(	_
35-15	5564-5567	+20	_
35-16	5568-5569	,	_
35-17	5570-5573	+40	_
35-18	5574-5575	,	_
35-19	5576-5579	+80	_
35-20	5580-5581	)	_
35-21	5582-5583	,	_
35-22	5584-5586	24	_
35-23	5587-5595	punished	_
35-24	5596-5599	−40	_
35-25	5600-5601	,	_
35-26	5602-5605	and	_
35-27	5606-5608	18	_
35-28	5609-5617	punished	_
35-29	5618-5621	−80	_
35-30	5622-5628	trials	_
35-31	5629-5630	.	_

Text=In addition to potential losses due to slow or non-responses on rewarded trials, the RGT design led to each participant receiving a different amount of −40 and −80 trials.
36-1	5631-5633	In	_
36-2	5634-5642	addition	_
36-3	5643-5645	to	_
36-4	5646-5655	potential	_
36-5	5656-5662	losses	_
36-6	5663-5666	due	_
36-7	5667-5669	to	_
36-8	5670-5674	slow	_
36-9	5675-5677	or	_
36-10	5678-5691	non-responses	_
36-11	5692-5694	on	_
36-12	5695-5703	rewarded	_
36-13	5704-5710	trials	_
36-14	5711-5712	,	_
36-15	5713-5716	the	_
36-16	5717-5720	RGT	_
36-17	5721-5727	design	_
36-18	5728-5731	led	_
36-19	5732-5734	to	_
36-20	5735-5739	each	_
36-21	5740-5751	participant	_
36-22	5752-5761	receiving	_
36-23	5762-5763	a	_
36-24	5764-5773	different	_
36-25	5774-5780	amount	_
36-26	5781-5783	of	_
36-27	5784-5787	−40	_
36-28	5788-5791	and	_
36-29	5792-5795	−80	_
36-30	5796-5802	trials	_
36-31	5803-5804	.	_

Text=If a participant pressed to collect 20 on a trial meant to be a −40 trial, or tried to collect 20 or 40 on a dedicated −80 trial, the subject received the collected amount, therein reducing the number of punished trials.
37-1	5805-5807	If	_
37-2	5808-5809	a	_
37-3	5810-5821	participant	_
37-4	5822-5829	pressed	_
37-5	5830-5832	to	_
37-6	5833-5840	collect	_
37-7	5841-5843	20	_
37-8	5844-5846	on	_
37-9	5847-5848	a	_
37-10	5849-5854	trial	_
37-11	5855-5860	meant	_
37-12	5861-5863	to	_
37-13	5864-5866	be	_
37-14	5867-5868	a	_
37-15	5869-5872	−40	_
37-16	5873-5878	trial	_
37-17	5879-5880	,	_
37-18	5881-5883	or	_
37-19	5884-5889	tried	_
37-20	5890-5892	to	_
37-21	5893-5900	collect	_
37-22	5901-5903	20	_
37-23	5904-5906	or	_
37-24	5907-5909	40	_
37-25	5910-5912	on	_
37-26	5913-5914	a	_
37-27	5915-5924	dedicated	_
37-28	5925-5928	−80	_
37-29	5929-5934	trial	_
37-30	5935-5936	,	_
37-31	5937-5940	the	_
37-32	5941-5948	subject	_
37-33	5949-5957	received	_
37-34	5958-5961	the	_
37-35	5962-5971	collected	_
37-36	5972-5978	amount	_
37-37	5979-5980	,	_
37-38	5981-5988	therein	_
37-39	5989-5997	reducing	_
37-40	5998-6001	the	_
37-41	6002-6008	number	_
37-42	6009-6011	of	_
37-43	6012-6020	punished	_
37-44	6021-6027	trials	_
37-45	6028-6029	.	_

Text=Image Acquisition The scanning session lasted approximately 60m and included an anatomical scan as well as four functional tasks: Stop-Signal, Paper Rock Scissors, two choice prediction, and RGT.
38-1	6030-6035	Image	_
38-2	6036-6047	Acquisition	_
38-3	6048-6051	The	_
38-4	6052-6060	scanning	_
38-5	6061-6068	session	_
38-6	6069-6075	lasted	_
38-7	6076-6089	approximately	_
38-8	6090-6093	60m	_
38-9	6094-6097	and	_
38-10	6098-6106	included	_
38-11	6107-6109	an	_
38-12	6110-6120	anatomical	_
38-13	6121-6125	scan	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
38-14	6126-6128	as	_
38-15	6129-6133	well	_
38-16	6134-6136	as	_
38-17	6137-6141	four	_
38-18	6142-6152	functional	_
38-19	6153-6158	tasks	_
38-20	6159-6160	:	_
38-21	6161-6172	Stop-Signal	_
38-22	6173-6174	,	_
38-23	6175-6180	Paper	_
38-24	6181-6185	Rock	_
38-25	6186-6194	Scissors	_
38-26	6195-6196	,	_
38-27	6197-6200	two	_
38-28	6201-6207	choice	_
38-29	6208-6218	prediction	_
38-30	6219-6220	,	_
38-31	6221-6224	and	_
38-32	6225-6228	RGT	_
38-33	6229-6230	.	_

Text=Prior to scanner entry, a brief RGT training session was conducted.
39-1	6231-6236	Prior	_
39-2	6237-6239	to	_
39-3	6240-6247	scanner	_
39-4	6248-6253	entry	_
39-5	6254-6255	,	_
39-6	6256-6257	a	_
39-7	6258-6263	brief	_
39-8	6264-6267	RGT	_
39-9	6268-6276	training	_
39-10	6277-6284	session	_
39-11	6285-6288	was	_
39-12	6289-6298	conducted	_
39-13	6299-6300	.	_

Text=The RGT was administered as a randomized fast-event related design, time-locked to the onset of 256 whole brain acquisitions (T2 * -weighted EPI on a Signa EXCITE, GE Healthcare, Milwaukee, Wisconsin, 3T scanner; TR = 2000 ms, TE = 32ms, FoV = 230x230 mm2, 64x64 matrix, 30 2.6-mm axial slices, 1.4 mm gap, flip angle= 90°, duration: 8m, 32s).
40-1	6301-6304	The	_
40-2	6305-6308	RGT	_
40-3	6309-6312	was	_
40-4	6313-6325	administered	_
40-5	6326-6328	as	_
40-6	6329-6330	a	_
40-7	6331-6341	randomized	_
40-8	6342-6352	fast-event	_
40-9	6353-6360	related	_
40-10	6361-6367	design	_
40-11	6368-6369	,	_
40-12	6370-6381	time-locked	_
40-13	6382-6384	to	_
40-14	6385-6388	the	_
40-15	6389-6394	onset	_
40-16	6395-6397	of	_
40-17	6398-6401	256	_
40-18	6402-6407	whole	_
40-19	6408-6413	brain	_
40-20	6414-6426	acquisitions	_
40-21	6427-6428	(	_
40-22	6429-6431	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-23	6432-6433	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-24	6434-6443	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-25	6444-6447	EPI	_
40-26	6448-6450	on	_
40-27	6451-6452	a	_
40-28	6453-6458	Signa	_
40-29	6459-6465	EXCITE	_
40-30	6466-6467	,	_
40-31	6468-6470	GE	_
40-32	6471-6481	Healthcare	_
40-33	6482-6483	,	_
40-34	6484-6493	Milwaukee	_
40-35	6494-6495	,	_
40-36	6496-6505	Wisconsin	_
40-37	6506-6507	,	_
40-38	6508-6510	3T	_
40-39	6511-6518	scanner	_
40-40	6519-6520	;	_
40-41	6521-6523	TR	_
40-42	6524-6525	=	_
40-43	6526-6530	2000	_
40-44	6531-6533	ms	_
40-45	6534-6535	,	_
40-46	6536-6538	TE	_
40-47	6539-6540	=	_
40-48	6541-6545	32ms	_
40-49	6546-6547	,	_
40-50	6548-6551	FoV	_
40-51	6552-6553	=	_
40-52	6554-6561	230x230	_
40-53	6562-6565	mm2	_
40-54	6566-6567	,	_
40-55	6568-6573	64x64	_
40-56	6574-6580	matrix	_
40-57	6581-6582	,	_
40-58	6583-6585	30	_
40-59	6586-6592	2.6-mm	_
40-60	6593-6598	axial	_
40-61	6599-6605	slices	_
40-62	6606-6607	,	_
40-63	6608-6611	1.4	_
40-64	6612-6614	mm	_
40-65	6615-6618	gap	_
40-66	6619-6620	,	_
40-67	6621-6625	flip	_
40-68	6626-6632	angle=	_
40-69	6633-6636	90°	_
40-70	6637-6638	,	_
40-71	6639-6647	duration	_
40-72	6648-6649	:	_
40-73	6650-6652	8m	_
40-74	6653-6654	,	_
40-75	6655-6658	32s	_
40-76	6659-6660	)	_
40-77	6661-6662	.	_

Text=Six resting-state trials were intermixed throughout the 96 trials and were not used in analysis.
41-1	6663-6666	Six	_
41-2	6667-6680	resting-state	_
41-3	6681-6687	trials	_
41-4	6688-6692	were	_
41-5	6693-6703	intermixed	_
41-6	6704-6714	throughout	_
41-7	6715-6718	the	_
41-8	6719-6721	96	_
41-9	6722-6728	trials	_
41-10	6729-6732	and	_
41-11	6733-6737	were	_
41-12	6738-6741	not	_
41-13	6742-6746	used	_
41-14	6747-6749	in	_
41-15	6750-6758	analysis	_
41-16	6759-6760	.	_

Text=A high-resolution T1-weight image (TR = 8ms, TE =3msec, FoV = 250x250 mm2, 192x256 matrix interpolated to a 256x256 matrix, flip angle= 12°, 172 sagittally acquired slices, .97x.97x1 mm3 voxels) was also obtained as a reference.
42-1	6761-6762	A	_
42-2	6763-6778	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
42-3	6779-6788	T1-weight	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-4	6789-6794	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-5	6795-6796	(	_
42-6	6797-6799	TR	_
42-7	6800-6801	=	_
42-8	6802-6805	8ms	_
42-9	6806-6807	,	_
42-10	6808-6810	TE	_
42-11	6811-6817	=3msec	_
42-12	6818-6819	,	_
42-13	6820-6823	FoV	_
42-14	6824-6825	=	_
42-15	6826-6833	250x250	_
42-16	6834-6837	mm2	_
42-17	6838-6839	,	_
42-18	6840-6847	192x256	_
42-19	6848-6854	matrix	_
42-20	6855-6867	interpolated	_
42-21	6868-6870	to	_
42-22	6871-6872	a	_
42-23	6873-6880	256x256	_
42-24	6881-6887	matrix	_
42-25	6888-6889	,	_
42-26	6890-6894	flip	_
42-27	6895-6901	angle=	_
42-28	6902-6905	12°	_
42-29	6906-6907	,	_
42-30	6908-6911	172	_
42-31	6912-6922	sagittally	_
42-32	6923-6931	acquired	_
42-33	6932-6938	slices	_
42-34	6939-6940	,	_
42-35	6941-6950	.97x.97x1	_
42-36	6951-6954	mm3	_
42-37	6955-6961	voxels	_
42-38	6962-6963	)	_
42-39	6964-6967	was	_
42-40	6968-6972	also	_
42-41	6973-6981	obtained	_
42-42	6982-6984	as	_
42-43	6985-6986	a	_
42-44	6987-6996	reference	_
42-45	6997-6998	.	_

Text=Three Year Follow-Up Interview OSU participated in another standardized interview three years after their baseline sessions (Figure 1), by phone or in-person, to assess drug use severity in the interim period.
43-1	6999-7004	Three	_
43-2	7005-7009	Year	_
43-3	7010-7019	Follow-Up	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
43-4	7020-7029	Interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
43-5	7030-7033	OSU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
43-6	7034-7046	participated	_
43-7	7047-7049	in	_
43-8	7050-7057	another	_
43-9	7058-7070	standardized	_
43-10	7071-7080	interview	_
43-11	7081-7086	three	_
43-12	7087-7092	years	_
43-13	7093-7098	after	_
43-14	7099-7104	their	_
43-15	7105-7113	baseline	_
43-16	7114-7122	sessions	_
43-17	7123-7124	(	_
43-18	7125-7131	Figure	_
43-19	7132-7133	1	_
43-20	7134-7135	)	_
43-21	7136-7137	,	_
43-22	7138-7140	by	_
43-23	7141-7146	phone	_
43-24	7147-7149	or	_
43-25	7150-7159	in-person	_
43-26	7160-7161	,	_
43-27	7162-7164	to	_
43-28	7165-7171	assess	_
43-29	7172-7176	drug	_
43-30	7177-7180	use	_
43-31	7181-7189	severity	_
43-32	7190-7192	in	_
43-33	7193-7196	the	_
43-34	7197-7204	interim	_
43-35	7205-7211	period	_
43-36	7212-7213	.	_

Text=Analyses were conducted using both categorical and dimensional definitions of interim stimulant use as recommended by Rabin and Moeller.
44-1	7214-7222	Analyses	_
44-2	7223-7227	were	_
44-3	7228-7237	conducted	_
44-4	7238-7243	using	_
44-5	7244-7248	both	_
44-6	7249-7260	categorical	_
44-7	7261-7264	and	_
44-8	7265-7276	dimensional	_
44-9	7277-7288	definitions	_
44-10	7289-7291	of	_
44-11	7292-7299	interim	_
44-12	7300-7309	stimulant	_
44-13	7310-7313	use	_
44-14	7314-7316	as	_
44-15	7317-7328	recommended	_
44-16	7329-7331	by	_
44-17	7332-7337	Rabin	_
44-18	7338-7341	and	_
44-19	7342-7349	Moeller	_
44-20	7350-7351	.	_

Text=For categorical analyses, participants were grouped into two categories: PSU or DSU.
45-1	7352-7355	For	_
45-2	7356-7367	categorical	_
45-3	7368-7376	analyses	_
45-4	7377-7378	,	_
45-5	7379-7391	participants	_
45-6	7392-7396	were	_
45-7	7397-7404	grouped	_
45-8	7405-7409	into	_
45-9	7410-7413	two	_
45-10	7414-7424	categories	_
45-11	7425-7426	:	_
45-12	7427-7430	PSU	_
45-13	7431-7433	or	_
45-14	7434-7437	DSU	_
45-15	7438-7439	.	_

Text=PSU (n=35) were a priori defined based on the current DSM-V criteria for SUD: 1) continued stimulant use since baseline; and 2) endorsement of 2+ DSM-IV symptoms of stimulant abuse or dependence occurring together for 6+ consecutive interim months.
46-1	7440-7443	PSU	_
46-2	7444-7445	(	_
46-3	7446-7450	n=35	_
46-4	7451-7452	)	_
46-5	7453-7457	were	_
46-6	7458-7459	a	_
46-7	7460-7466	priori	_
46-8	7467-7474	defined	_
46-9	7475-7480	based	_
46-10	7481-7483	on	_
46-11	7484-7487	the	_
46-12	7488-7495	current	_
46-13	7496-7501	DSM-V	_
46-14	7502-7510	criteria	_
46-15	7511-7514	for	_
46-16	7515-7518	SUD	_
46-17	7519-7520	:	_
46-18	7521-7522	1	_
46-19	7523-7524	)	_
46-20	7525-7534	continued	_
46-21	7535-7544	stimulant	_
46-22	7545-7548	use	_
46-23	7549-7554	since	_
46-24	7555-7563	baseline	_
46-25	7564-7565	;	_
46-26	7566-7569	and	_
46-27	7570-7571	2	_
46-28	7572-7573	)	_
46-29	7574-7585	endorsement	_
46-30	7586-7588	of	_
46-31	7589-7591	2+	_
46-32	7592-7598	DSM-IV	_
46-33	7599-7607	symptoms	_
46-34	7608-7610	of	_
46-35	7611-7620	stimulant	_
46-36	7621-7626	abuse	_
46-37	7627-7629	or	_
46-38	7630-7640	dependence	_
46-39	7641-7650	occurring	_
46-40	7651-7659	together	_
46-41	7660-7663	for	_
46-42	7664-7666	6+	_
46-43	7667-7678	consecutive	_
46-44	7679-7686	interim	_
46-45	7687-7693	months	_
46-46	7694-7695	.	_

Text=Within PSU, 51% met criteria for cocaine abuse, 23% met criteria for cocaine dependence, 46% met criteria for amphetamine abuse and 17% met criteria for amphetamine dependence.
47-1	7696-7702	Within	_
47-2	7703-7706	PSU	http://maven.renci.org/NeuroBridge/neurobridge#Thing
47-3	7707-7708	,	_
47-4	7709-7711	51	_
47-5	7712-7713	%	_
47-6	7714-7717	met	_
47-7	7718-7726	criteria	_
47-8	7727-7730	for	_
47-9	7731-7738	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
47-10	7739-7744	abuse	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
47-11	7745-7746	,	_
47-12	7747-7749	23	_
47-13	7750-7751	%	_
47-14	7752-7755	met	_
47-15	7756-7764	criteria	_
47-16	7765-7768	for	_
47-17	7769-7776	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
47-18	7777-7787	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
47-19	7788-7789	,	_
47-20	7790-7792	46	_
47-21	7793-7794	%	_
47-22	7795-7798	met	_
47-23	7799-7807	criteria	_
47-24	7808-7811	for	_
47-25	7812-7823	amphetamine	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
47-26	7824-7829	abuse	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineAbuse
47-27	7830-7833	and	_
47-28	7834-7836	17	_
47-29	7837-7838	%	_
47-30	7839-7842	met	_
47-31	7843-7851	criteria	_
47-32	7852-7855	for	_
47-33	7856-7867	amphetamine	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
47-34	7868-7878	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
47-35	7879-7880	.	_

Text=DSU (n=75) were defined based on the emphasis of the choice to desist as a critical part of addiction recovery models and in the prevention of transition to SUD: 1) no 6-month periods of 3+ stimulant uses; and 2) no endorsement of interim SUD symptoms.
48-1	7881-7884	DSU	_
48-2	7885-7886	(	_
48-3	7887-7891	n=75	_
48-4	7892-7893	)	_
48-5	7894-7898	were	_
48-6	7899-7906	defined	_
48-7	7907-7912	based	_
48-8	7913-7915	on	_
48-9	7916-7919	the	_
48-10	7920-7928	emphasis	_
48-11	7929-7931	of	_
48-12	7932-7935	the	_
48-13	7936-7942	choice	_
48-14	7943-7945	to	_
48-15	7946-7952	desist	_
48-16	7953-7955	as	_
48-17	7956-7957	a	_
48-18	7958-7966	critical	_
48-19	7967-7971	part	_
48-20	7972-7974	of	_
48-21	7975-7984	addiction	_
48-22	7985-7993	recovery	_
48-23	7994-8000	models	_
48-24	8001-8004	and	_
48-25	8005-8007	in	_
48-26	8008-8011	the	_
48-27	8012-8022	prevention	_
48-28	8023-8025	of	_
48-29	8026-8036	transition	_
48-30	8037-8039	to	_
48-31	8040-8043	SUD	_
48-32	8044-8045	:	_
48-33	8046-8047	1	_
48-34	8048-8049	)	_
48-35	8050-8052	no	_
48-36	8053-8060	6-month	_
48-37	8061-8068	periods	_
48-38	8069-8071	of	_
48-39	8072-8074	3+	_
48-40	8075-8084	stimulant	_
48-41	8085-8089	uses	_
48-42	8090-8091	;	_
48-43	8092-8095	and	_
48-44	8096-8097	2	_
48-45	8098-8099	)	_
48-46	8100-8102	no	_
48-47	8103-8114	endorsement	_
48-48	8115-8117	of	_
48-49	8118-8125	interim	_
48-50	8126-8129	SUD	_
48-51	8130-8138	symptoms	_
48-52	8139-8140	.	_

Text=OSU who did not meet criteria for either PSU or DSU (n=34) were excluded from categorical analyses because of the highly variable nature of those who did not fit either category (e.g.
49-1	8141-8144	OSU	_
49-2	8145-8148	who	_
49-3	8149-8152	did	_
49-4	8153-8156	not	_
49-5	8157-8161	meet	_
49-6	8162-8170	criteria	_
49-7	8171-8174	for	_
49-8	8175-8181	either	_
49-9	8182-8185	PSU	_
49-10	8186-8188	or	_
49-11	8189-8192	DSU	_
49-12	8193-8194	(	_
49-13	8195-8199	n=34	_
49-14	8200-8201	)	_
49-15	8202-8206	were	_
49-16	8207-8215	excluded	_
49-17	8216-8220	from	_
49-18	8221-8232	categorical	_
49-19	8233-8241	analyses	_
49-20	8242-8249	because	_
49-21	8250-8252	of	_
49-22	8253-8256	the	_
49-23	8257-8263	highly	_
49-24	8264-8272	variable	_
49-25	8273-8279	nature	_
49-26	8280-8282	of	_
49-27	8283-8288	those	_
49-28	8289-8292	who	_
49-29	8293-8296	did	_
49-30	8297-8300	not	_
49-31	8301-8304	fit	_
49-32	8305-8311	either	_
49-33	8312-8320	category	_
49-34	8321-8322	(	_
49-35	8323-8326	e.g	_
49-36	8327-8328	.	_

Text=met only 1 abuse/dependence criteria, used too many times in interim but no accompanying symptoms, etc.
50-1	8329-8332	met	_
50-2	8333-8337	only	_
50-3	8338-8339	1	_
50-4	8340-8356	abuse/dependence	_
50-5	8357-8365	criteria	_
50-6	8366-8367	,	_
50-7	8368-8372	used	_
50-8	8373-8376	too	_
50-9	8377-8381	many	_
50-10	8382-8387	times	_
50-11	8388-8390	in	_
50-12	8391-8398	interim	_
50-13	8399-8402	but	_
50-14	8403-8405	no	_
50-15	8406-8418	accompanying	_
50-16	8419-8427	symptoms	_
50-17	8428-8429	,	_
50-18	8430-8433	etc	_
50-19	8434-8435	.	_

Text=).Dimensional analyses were conducted using all OSU (n=144), wherein RGT BOLD signals were correlated with baseline and interim stimulant and marijuana uses (quantified as total sessions).
51-1	8436-8437	)	_
51-2	8438-8450	.Dimensional	_
51-3	8451-8459	analyses	_
51-4	8460-8464	were	_
51-5	8465-8474	conducted	_
51-6	8475-8480	using	_
51-7	8481-8484	all	_
51-8	8485-8488	OSU	_
51-9	8489-8490	(	_
51-10	8491-8496	n=144	_
51-11	8497-8498	)	_
51-12	8499-8500	,	_
51-13	8501-8508	wherein	_
51-14	8509-8512	RGT	_
51-15	8513-8517	BOLD	_
51-16	8518-8525	signals	_
51-17	8526-8530	were	_
51-18	8531-8541	correlated	_
51-19	8542-8546	with	_
51-20	8547-8555	baseline	_
51-21	8556-8559	and	_
51-22	8560-8567	interim	_
51-23	8568-8577	stimulant	_
51-24	8578-8581	and	_
51-25	8582-8591	marijuana	_
51-26	8592-8596	uses	_
51-27	8597-8598	(	_
51-28	8599-8609	quantified	_
51-29	8610-8612	as	_
51-30	8613-8618	total	_
51-31	8619-8627	sessions	_
51-32	8628-8629	)	_
51-33	8630-8631	.	_

Text=Data Analysis Baseline Characteristics and Behavior Group differences in age, IQ, education, drug use, and RGT behavior were compared in SPSS by independent samples t-tests, whereas differences in gender, race/ethnicity, and handedness were analyzed using chi-square tests (Table 1).
52-1	8632-8636	Data	_
52-2	8637-8645	Analysis	_
52-3	8646-8654	Baseline	_
52-4	8655-8670	Characteristics	_
52-5	8671-8674	and	_
52-6	8675-8683	Behavior	_
52-7	8684-8689	Group	_
52-8	8690-8701	differences	_
52-9	8702-8704	in	_
52-10	8705-8708	age	_
52-11	8709-8710	,	_
52-12	8711-8713	IQ	_
52-13	8714-8715	,	_
52-14	8716-8725	education	_
52-15	8726-8727	,	_
52-16	8728-8732	drug	_
52-17	8733-8736	use	_
52-18	8737-8738	,	_
52-19	8739-8742	and	_
52-20	8743-8746	RGT	_
52-21	8747-8755	behavior	_
52-22	8756-8760	were	_
52-23	8761-8769	compared	_
52-24	8770-8772	in	_
52-25	8773-8777	SPSS	_
52-26	8778-8780	by	_
52-27	8781-8792	independent	_
52-28	8793-8800	samples	_
52-29	8801-8808	t-tests	_
52-30	8809-8810	,	_
52-31	8811-8818	whereas	_
52-32	8819-8830	differences	_
52-33	8831-8833	in	_
52-34	8834-8840	gender	_
52-35	8841-8842	,	_
52-36	8843-8857	race/ethnicity	_
52-37	8858-8859	,	_
52-38	8860-8863	and	_
52-39	8864-8874	handedness	_
52-40	8875-8879	were	_
52-41	8880-8888	analyzed	_
52-42	8889-8894	using	_
52-43	8895-8905	chi-square	_
52-44	8906-8911	tests	_
52-45	8912-8913	(	_
52-46	8914-8919	Table	_
52-47	8920-8921	1	_
52-48	8922-8923	)	_
52-49	8924-8925	.	_

Text=To evaluate whether follow-up status differed as a function of baseline preferred stimulant type (cocaine versus prescription amphetamines) or in relation to the history of/presence of comorbid alcohol and marijuana abuse or dependence, chi-square analyses were performed.
53-1	8926-8928	To	_
53-2	8929-8937	evaluate	_
53-3	8938-8945	whether	_
53-4	8946-8955	follow-up	_
53-5	8956-8962	status	_
53-6	8963-8971	differed	_
53-7	8972-8974	as	_
53-8	8975-8976	a	_
53-9	8977-8985	function	_
53-10	8986-8988	of	_
53-11	8989-8997	baseline	_
53-12	8998-9007	preferred	_
53-13	9008-9017	stimulant	_
53-14	9018-9022	type	_
53-15	9023-9024	(	_
53-16	9025-9032	cocaine	_
53-17	9033-9039	versus	_
53-18	9040-9052	prescription	_
53-19	9053-9065	amphetamines	_
53-20	9066-9067	)	_
53-21	9068-9070	or	_
53-22	9071-9073	in	_
53-23	9074-9082	relation	_
53-24	9083-9085	to	_
53-25	9086-9089	the	_
53-26	9090-9097	history	_
53-27	9098-9109	of/presence	_
53-28	9110-9112	of	_
53-29	9113-9121	comorbid	_
53-30	9122-9129	alcohol	_
53-31	9130-9133	and	_
53-32	9134-9143	marijuana	_
53-33	9144-9149	abuse	_
53-34	9150-9152	or	_
53-35	9153-9163	dependence	_
53-36	9164-9165	,	_
53-37	9166-9176	chi-square	_
53-38	9177-9185	analyses	_
53-39	9186-9190	were	_
53-40	9191-9200	performed	_
53-41	9201-9202	.	_

Text=RGT The RGT was analyzed in two stages.
54-1	9203-9206	RGT	_
54-2	9207-9210	The	_
54-3	9211-9214	RGT	_
54-4	9215-9218	was	_
54-5	9219-9227	analyzed	_
54-6	9228-9230	in	_
54-7	9231-9234	two	_
54-8	9235-9241	stages	_
54-9	9242-9243	.	_

Text=First, decision contrasts evaluated differences between groups when individuals made a “ risky ” (+/− 40; +/−80) versus “ safe ” (+20) decision.
55-1	9244-9249	First	_
55-2	9250-9251	,	_
55-3	9252-9260	decision	_
55-4	9261-9270	contrasts	_
55-5	9271-9280	evaluated	_
55-6	9281-9292	differences	_
55-7	9293-9300	between	_
55-8	9301-9307	groups	_
55-9	9308-9312	when	_
55-10	9313-9324	individuals	_
55-11	9325-9329	made	_
55-12	9330-9331	a	_
55-13	9332-9333	“	_
55-14	9334-9339	risky	_
55-15	9340-9341	”	_
55-16	9342-9343	(	_
55-17	9344-9347	+/−	_
55-18	9348-9350	40	_
55-19	9351-9352	;	_
55-20	9353-9358	+/−80	_
55-21	9359-9360	)	_
55-22	9361-9367	versus	_
55-23	9368-9369	“	_
55-24	9370-9374	safe	_
55-25	9375-9376	”	_
55-26	9377-9378	(	_
55-27	9379-9382	+20	_
55-28	9383-9384	)	_
55-29	9385-9393	decision	_
55-30	9394-9395	.	_

Text=All risky responses were combined to create a relatively even split between risky and safe decisions.
56-1	9396-9399	All	_
56-2	9400-9405	risky	_
56-3	9406-9415	responses	_
56-4	9416-9420	were	_
56-5	9421-9429	combined	_
56-6	9430-9432	to	_
56-7	9433-9439	create	_
56-8	9440-9441	a	_
56-9	9442-9452	relatively	_
56-10	9453-9457	even	_
56-11	9458-9463	split	_
56-12	9464-9471	between	_
56-13	9472-9477	risky	_
56-14	9478-9481	and	_
56-15	9482-9486	safe	_
56-16	9487-9496	decisions	_
56-17	9497-9498	.	_

Text=Second, outcome contrasts evaluated differences in response after wins (+40; +80) versus losses (−40; −80) on risky trials; participants without 5 of each trial type (safe versus risky (40 or 80)) were excluded from analysis.
57-1	9499-9505	Second	_
57-2	9506-9507	,	_
57-3	9508-9515	outcome	_
57-4	9516-9525	contrasts	_
57-5	9526-9535	evaluated	_
57-6	9536-9547	differences	_
57-7	9548-9550	in	_
57-8	9551-9559	response	_
57-9	9560-9565	after	_
57-10	9566-9570	wins	_
57-11	9571-9572	(	_
57-12	9573-9576	+40	_
57-13	9577-9578	;	_
57-14	9579-9582	+80	_
57-15	9583-9584	)	_
57-16	9585-9591	versus	_
57-17	9592-9598	losses	_
57-18	9599-9600	(	_
57-19	9601-9604	−40	_
57-20	9605-9606	;	_
57-21	9607-9610	−80	_
57-22	9611-9612	)	_
57-23	9613-9615	on	_
57-24	9616-9621	risky	_
57-25	9622-9628	trials	_
57-26	9629-9630	;	_
57-27	9631-9643	participants	_
57-28	9644-9651	without	_
57-29	9652-9653	5	_
57-30	9654-9656	of	_
57-31	9657-9661	each	_
57-32	9662-9667	trial	_
57-33	9668-9672	type	_
57-34	9673-9674	(	_
57-35	9675-9679	safe	_
57-36	9680-9686	versus	_
57-37	9687-9692	risky	_
57-38	9693-9694	(	_
57-39	9695-9697	40	_
57-40	9698-9700	or	_
57-41	9701-9703	80	_
57-42	9704-9705	)	_
57-43	9706-9707	)	_
57-44	9708-9712	were	_
57-45	9713-9721	excluded	_
57-46	9722-9726	from	_
57-47	9727-9735	analysis	_
57-48	9736-9737	.	_

Text=Neuroimaging MRI data were analyzed using Analysis of Functional Neuroimages (AFNI).
58-1	9738-9750	Neuroimaging	_
58-2	9751-9754	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
58-3	9755-9759	data	_
58-4	9760-9764	were	_
58-5	9765-9773	analyzed	_
58-6	9774-9779	using	_
58-7	9780-9788	Analysis	_
58-8	9789-9791	of	_
58-9	9792-9802	Functional	_
58-10	9803-9814	Neuroimages	_
58-11	9815-9816	(	_
58-12	9817-9821	AFNI	_
58-13	9822-9823	)	_
58-14	9824-9825	.	_

Text=Single subject data preprocessing procedures are outlined in Reske et al ..
59-1	9826-9832	Single	_
59-2	9833-9840	subject	_
59-3	9841-9845	data	_
59-4	9846-9859	preprocessing	_
59-5	9860-9870	procedures	_
59-6	9871-9874	are	_
59-7	9875-9883	outlined	_
59-8	9884-9886	in	_
59-9	9887-9892	Reske	_
59-10	9893-9895	et	_
59-11	9896-9898	al	_
59-12	9899-9901	..	_

Text=Multiple regressor analysis and individual linear contrasts were computed in 3dDeconvolve, including six motion regressors as well as baseline and linear drift.
60-1	9902-9910	Multiple	_
60-2	9911-9920	regressor	_
60-3	9921-9929	analysis	_
60-4	9930-9933	and	_
60-5	9934-9944	individual	_
60-6	9945-9951	linear	_
60-7	9952-9961	contrasts	_
60-8	9962-9966	were	_
60-9	9967-9975	computed	_
60-10	9976-9978	in	_
60-11	9979-9991	3dDeconvolve	_
60-12	9992-9993	,	_
60-13	9994-10003	including	_
60-14	10004-10007	six	_
60-15	10008-10014	motion	_
60-16	10015-10025	regressors	_
60-17	10026-10028	as	_
60-18	10029-10033	well	_
60-19	10034-10036	as	_
60-20	10037-10045	baseline	_
60-21	10046-10049	and	_
60-22	10050-10056	linear	_
60-23	10057-10062	drift	_
60-24	10063-10064	.	_

Text=Deconvolution was performed to examine the decision contrast (risky = +/−40, +/−80; safe = +20) and outcome contrast (risky wins = +40, +80; risky losses = −40, −80).
61-1	10065-10078	Deconvolution	_
61-2	10079-10082	was	_
61-3	10083-10092	performed	_
61-4	10093-10095	to	_
61-5	10096-10103	examine	_
61-6	10104-10107	the	_
61-7	10108-10116	decision	_
61-8	10117-10125	contrast	_
61-9	10126-10127	(	_
61-10	10128-10133	risky	_
61-11	10134-10135	=	_
61-12	10136-10141	+/−40	_
61-13	10142-10143	,	_
61-14	10144-10149	+/−80	_
61-15	10150-10151	;	_
61-16	10152-10156	safe	_
61-17	10157-10158	=	_
61-18	10159-10162	+20	_
61-19	10163-10164	)	_
61-20	10165-10168	and	_
61-21	10169-10176	outcome	_
61-22	10177-10185	contrast	_
61-23	10186-10187	(	_
61-24	10188-10193	risky	_
61-25	10194-10198	wins	_
61-26	10199-10200	=	_
61-27	10201-10204	+40	_
61-28	10205-10206	,	_
61-29	10207-10210	+80	_
61-30	10211-10212	;	_
61-31	10213-10218	risky	_
61-32	10219-10225	losses	_
61-33	10226-10227	=	_
61-34	10228-10231	−40	_
61-35	10232-10233	,	_
61-36	10234-10237	−80	_
61-37	10238-10239	)	_
61-38	10240-10241	.	_

Text=Voxels were resampled into 4×4×4-mm3 space and whole-brain voxel-wise normalized percent signal change, the main dependent measure, was determined by dividing the beta coefficient for each of the predictors of interest (BOLD signal for risky versus safe decisions and risky wins versus risky losses) by the beta coefficient for the baseline regressor and multiplying by 100.
62-1	10242-10248	Voxels	_
62-2	10249-10253	were	_
62-3	10254-10263	resampled	_
62-4	10264-10268	into	_
62-5	10269-10278	4×4×4-mm3	_
62-6	10279-10284	space	_
62-7	10285-10288	and	_
62-8	10289-10300	whole-brain	_
62-9	10301-10311	voxel-wise	_
62-10	10312-10322	normalized	_
62-11	10323-10330	percent	_
62-12	10331-10337	signal	_
62-13	10338-10344	change	_
62-14	10345-10346	,	_
62-15	10347-10350	the	_
62-16	10351-10355	main	_
62-17	10356-10365	dependent	_
62-18	10366-10373	measure	_
62-19	10374-10375	,	_
62-20	10376-10379	was	_
62-21	10380-10390	determined	_
62-22	10391-10393	by	_
62-23	10394-10402	dividing	_
62-24	10403-10406	the	_
62-25	10407-10411	beta	_
62-26	10412-10423	coefficient	_
62-27	10424-10427	for	_
62-28	10428-10432	each	_
62-29	10433-10435	of	_
62-30	10436-10439	the	_
62-31	10440-10450	predictors	_
62-32	10451-10453	of	_
62-33	10454-10462	interest	_
62-34	10463-10464	(	_
62-35	10465-10469	BOLD	_
62-36	10470-10476	signal	_
62-37	10477-10480	for	_
62-38	10481-10486	risky	_
62-39	10487-10493	versus	_
62-40	10494-10498	safe	_
62-41	10499-10508	decisions	_
62-42	10509-10512	and	_
62-43	10513-10518	risky	_
62-44	10519-10523	wins	_
62-45	10524-10530	versus	_
62-46	10531-10536	risky	_
62-47	10537-10543	losses	_
62-48	10544-10545	)	_
62-49	10546-10548	by	_
62-50	10549-10552	the	_
62-51	10553-10557	beta	_
62-52	10558-10569	coefficient	_
62-53	10570-10573	for	_
62-54	10574-10577	the	_
62-55	10578-10586	baseline	_
62-56	10587-10596	regressor	_
62-57	10597-10600	and	_
62-58	10601-10612	multiplying	_
62-59	10613-10615	by	_
62-60	10616-10619	100	_
62-61	10620-10621	.	_

Text=A Gaussian spatial filter (4 mm full-width half-maximum; FWHM) blurred percent signal change values, which were then normalized to AFNI Talairach coordinates (40×48×38 voxel coverage).
63-1	10622-10623	A	_
63-2	10624-10632	Gaussian	_
63-3	10633-10640	spatial	_
63-4	10641-10647	filter	_
63-5	10648-10649	(	_
63-6	10650-10651	4	_
63-7	10652-10654	mm	_
63-8	10655-10665	full-width	_
63-9	10666-10678	half-maximum	_
63-10	10679-10680	;	_
63-11	10681-10685	FWHM	_
63-12	10686-10687	)	_
63-13	10688-10695	blurred	_
63-14	10696-10703	percent	_
63-15	10704-10710	signal	_
63-16	10711-10717	change	_
63-17	10718-10724	values	_
63-18	10725-10726	,	_
63-19	10727-10732	which	_
63-20	10733-10737	were	_
63-21	10738-10742	then	_
63-22	10743-10753	normalized	_
63-23	10754-10756	to	_
63-24	10757-10761	AFNI	_
63-25	10762-10771	Talairach	_
63-26	10772-10783	coordinates	_
63-27	10784-10785	(	_
63-28	10786-10794	40×48×38	_
63-29	10795-10800	voxel	_
63-30	10801-10809	coverage	_
63-31	10810-10811	)	_
63-32	10812-10813	.	_

Text=Individual-subject values for risky decisions, safe decisions, risky win outcomes, and risky loss outcomes for each voxel included in a whole-brain mask were extracted for statistical analyses.
64-1	10814-10832	Individual-subject	_
64-2	10833-10839	values	_
64-3	10840-10843	for	_
64-4	10844-10849	risky	_
64-5	10850-10859	decisions	_
64-6	10860-10861	,	_
64-7	10862-10866	safe	_
64-8	10867-10876	decisions	_
64-9	10877-10878	,	_
64-10	10879-10884	risky	_
64-11	10885-10888	win	_
64-12	10889-10897	outcomes	_
64-13	10898-10899	,	_
64-14	10900-10903	and	_
64-15	10904-10909	risky	_
64-16	10910-10914	loss	_
64-17	10915-10923	outcomes	_
64-18	10924-10927	for	_
64-19	10928-10932	each	_
64-20	10933-10938	voxel	_
64-21	10939-10947	included	_
64-22	10948-10950	in	_
64-23	10951-10952	a	_
64-24	10953-10964	whole-brain	_
64-25	10965-10969	mask	_
64-26	10970-10974	were	_
64-27	10975-10984	extracted	_
64-28	10985-10988	for	_
64-29	10989-11000	statistical	_
64-30	11001-11009	analyses	_
64-31	11010-11011	.	_

Text=Individual voxels meeting a p <0.01 significance criterion as a result of statistical tests outlined below were evaluated further to determine whether they comprised a significant brain cluster after correction for multiple comparisons.
65-1	11012-11022	Individual	_
65-2	11023-11029	voxels	_
65-3	11030-11037	meeting	_
65-4	11038-11039	a	_
65-5	11040-11041	p	_
65-6	11042-11043	<	_
65-7	11044-11048	0.01	_
65-8	11049-11061	significance	_
65-9	11062-11071	criterion	_
65-10	11072-11074	as	_
65-11	11075-11076	a	_
65-12	11077-11083	result	_
65-13	11084-11086	of	_
65-14	11087-11098	statistical	_
65-15	11099-11104	tests	_
65-16	11105-11113	outlined	_
65-17	11114-11119	below	_
65-18	11120-11124	were	_
65-19	11125-11134	evaluated	_
65-20	11135-11142	further	_
65-21	11143-11145	to	_
65-22	11146-11155	determine	_
65-23	11156-11163	whether	_
65-24	11164-11168	they	_
65-25	11169-11178	comprised	_
65-26	11179-11180	a	_
65-27	11181-11192	significant	_
65-28	11193-11198	brain	_
65-29	11199-11206	cluster	_
65-30	11207-11212	after	_
65-31	11213-11223	correction	_
65-32	11224-11227	for	_
65-33	11228-11236	multiple	_
65-34	11237-11248	comparisons	_
65-35	11249-11250	.	_

Text=Categorical analyses For each voxel, a linear mixed effects (LME) model was performed in R to identify significant regions of percent signal change between PSU and DSU, for decision and outcome analyses separately.
66-1	11251-11262	Categorical	_
66-2	11263-11271	analyses	_
66-3	11272-11275	For	_
66-4	11276-11280	each	_
66-5	11281-11286	voxel	_
66-6	11287-11288	,	_
66-7	11289-11290	a	_
66-8	11291-11297	linear	_
66-9	11298-11303	mixed	_
66-10	11304-11311	effects	_
66-11	11312-11313	(	_
66-12	11314-11317	LME	_
66-13	11318-11319	)	_
66-14	11320-11325	model	_
66-15	11326-11329	was	_
66-16	11330-11339	performed	_
66-17	11340-11342	in	_
66-18	11343-11344	R	_
66-19	11345-11347	to	_
66-20	11348-11356	identify	_
66-21	11357-11368	significant	_
66-22	11369-11376	regions	_
66-23	11377-11379	of	_
66-24	11380-11387	percent	_
66-25	11388-11394	signal	_
66-26	11395-11401	change	_
66-27	11402-11409	between	_
66-28	11410-11413	PSU	_
66-29	11414-11417	and	_
66-30	11418-11421	DSU	_
66-31	11422-11423	,	_
66-32	11424-11427	for	_
66-33	11428-11436	decision	_
66-34	11437-11440	and	_
66-35	11441-11448	outcome	_
66-36	11449-11457	analyses	_
66-37	11458-11468	separately	_
66-38	11469-11470	.	_

Text=Group was the between-subjects variable and subject was a random variable.
67-1	11471-11476	Group	_
67-2	11477-11480	was	_
67-3	11481-11484	the	_
67-4	11485-11501	between-subjects	_
67-5	11502-11510	variable	_
67-6	11511-11514	and	_
67-7	11515-11522	subject	_
67-8	11523-11526	was	_
67-9	11527-11528	a	_
67-10	11529-11535	random	_
67-11	11536-11544	variable	_
67-12	11545-11546	.	_

Text=Within-subject variables were decision type (risky versus safe) and outcome type (risky wins versus risky losses).
68-1	11547-11561	Within-subject	_
68-2	11562-11571	variables	_
68-3	11572-11576	were	_
68-4	11577-11585	decision	_
68-5	11586-11590	type	_
68-6	11591-11592	(	_
68-7	11593-11598	risky	_
68-8	11599-11605	versus	_
68-9	11606-11610	safe	_
68-10	11611-11612	)	_
68-11	11613-11616	and	_
68-12	11617-11624	outcome	_
68-13	11625-11629	type	_
68-14	11630-11631	(	_
68-15	11632-11637	risky	_
68-16	11638-11642	wins	_
68-17	11643-11649	versus	_
68-18	11650-11655	risky	_
68-19	11656-11662	losses	_
68-20	11663-11664	)	_
68-21	11665-11666	.	_

Text=Cohen ’ s d was calculated to determine effect sizes.
69-1	11667-11672	Cohen	_
69-2	11673-11674	’	_
69-3	11675-11676	s	_
69-4	11677-11678	d	_
69-5	11679-11682	was	_
69-6	11683-11693	calculated	_
69-7	11694-11696	to	_
69-8	11697-11706	determine	_
69-9	11707-11713	effect	_
69-10	11714-11719	sizes	_
69-11	11720-11721	.	_

Text=Dimensional analyses Multiple regressions were computed for each brain voxel, with two separate dependent variables: 1) percent signal change for risky minus safe decisions; and 2) percent signal change for risky wins minus losses.
70-1	11722-11733	Dimensional	_
70-2	11734-11742	analyses	_
70-3	11743-11751	Multiple	_
70-4	11752-11763	regressions	_
70-5	11764-11768	were	_
70-6	11769-11777	computed	_
70-7	11778-11781	for	_
70-8	11782-11786	each	_
70-9	11787-11792	brain	_
70-10	11793-11798	voxel	_
70-11	11799-11800	,	_
70-12	11801-11805	with	_
70-13	11806-11809	two	_
70-14	11810-11818	separate	_
70-15	11819-11828	dependent	_
70-16	11829-11838	variables	_
70-17	11839-11840	:	_
70-18	11841-11842	1	_
70-19	11843-11844	)	_
70-20	11845-11852	percent	_
70-21	11853-11859	signal	_
70-22	11860-11866	change	_
70-23	11867-11870	for	_
70-24	11871-11876	risky	_
70-25	11877-11882	minus	_
70-26	11883-11887	safe	_
70-27	11888-11897	decisions	_
70-28	11898-11899	;	_
70-29	11900-11903	and	_
70-30	11904-11905	2	_
70-31	11906-11907	)	_
70-32	11908-11915	percent	_
70-33	11916-11922	signal	_
70-34	11923-11929	change	_
70-35	11930-11933	for	_
70-36	11934-11939	risky	_
70-37	11940-11944	wins	_
70-38	11945-11950	minus	_
70-39	11951-11957	losses	_
70-40	11958-11959	.	_

Text=Predictors in each regression were the following: 1) baseline stimulant uses; 2) interim stimulant uses; 3) baseline marijuana uses; and 4) interim marijuana uses.
71-1	11960-11970	Predictors	_
71-2	11971-11973	in	_
71-3	11974-11978	each	_
71-4	11979-11989	regression	_
71-5	11990-11994	were	_
71-6	11995-11998	the	_
71-7	11999-12008	following	_
71-8	12009-12010	:	_
71-9	12011-12012	1	_
71-10	12013-12014	)	_
71-11	12015-12023	baseline	_
71-12	12024-12033	stimulant	_
71-13	12034-12038	uses	_
71-14	12039-12040	;	_
71-15	12041-12042	2	_
71-16	12043-12044	)	_
71-17	12045-12052	interim	_
71-18	12053-12062	stimulant	_
71-19	12063-12067	uses	_
71-20	12068-12069	;	_
71-21	12070-12071	3	_
71-22	12072-12073	)	_
71-23	12074-12082	baseline	_
71-24	12083-12092	marijuana	_
71-25	12093-12097	uses	_
71-26	12098-12099	;	_
71-27	12100-12103	and	_
71-28	12104-12105	4	_
71-29	12106-12107	)	_
71-30	12108-12115	interim	_
71-31	12116-12125	marijuana	_
71-32	12126-12130	uses	_
71-33	12131-12132	.	_

Text=All predictors were log-transformed due to non-normality and z-scored prior to regression entry.
72-1	12133-12136	All	_
72-2	12137-12147	predictors	_
72-3	12148-12152	were	_
72-4	12153-12168	log-transformed	_
72-5	12169-12172	due	_
72-6	12173-12175	to	_
72-7	12176-12189	non-normality	_
72-8	12190-12193	and	_
72-9	12194-12202	z-scored	_
72-10	12203-12208	prior	_
72-11	12209-12211	to	_
72-12	12212-12222	regression	_
72-13	12223-12228	entry	_
72-14	12229-12230	.	_

Text=Extracting significant whole-brain clusters Neuroimaging analysis software has been criticized for underestimating spatial autocorrelation, leading to insufficient multiple comparison corrections.
73-1	12231-12241	Extracting	_
73-2	12242-12253	significant	_
73-3	12254-12265	whole-brain	_
73-4	12266-12274	clusters	_
73-5	12275-12287	Neuroimaging	_
73-6	12288-12296	analysis	_
73-7	12297-12305	software	_
73-8	12306-12309	has	_
73-9	12310-12314	been	_
73-10	12315-12325	criticized	_
73-11	12326-12329	for	_
73-12	12330-12345	underestimating	_
73-13	12346-12353	spatial	_
73-14	12354-12369	autocorrelation	_
73-15	12370-12371	,	_
73-16	12372-12379	leading	_
73-17	12380-12382	to	_
73-18	12383-12395	insufficient	_
73-19	12396-12404	multiple	_
73-20	12405-12415	comparison	_
73-21	12416-12427	corrections	_
73-22	12428-12429	.	_

Text=In response to these concerns: 1) the updated 3dFWHMx program was employed to more reliably estimate true autocorrelation and smoothness present following blurring (5 mm); and 2) an updated version of 3dClustSim was run to account for autocorrelation given our voxel/whole-brain mask size, 10,000 Monte Carlo simulations and two-sided thresholding with an overall voxel p statistical threshold of 0.01 and a corrected clusterwise alpha value of 0.01.
74-1	12430-12432	In	_
74-2	12433-12441	response	_
74-3	12442-12444	to	_
74-4	12445-12450	these	_
74-5	12451-12459	concerns	_
74-6	12460-12461	:	_
74-7	12462-12463	1	_
74-8	12464-12465	)	_
74-9	12466-12469	the	_
74-10	12470-12477	updated	_
74-11	12478-12485	3dFWHMx	_
74-12	12486-12493	program	_
74-13	12494-12497	was	_
74-14	12498-12506	employed	_
74-15	12507-12509	to	_
74-16	12510-12514	more	_
74-17	12515-12523	reliably	_
74-18	12524-12532	estimate	_
74-19	12533-12537	true	_
74-20	12538-12553	autocorrelation	_
74-21	12554-12557	and	_
74-22	12558-12568	smoothness	_
74-23	12569-12576	present	_
74-24	12577-12586	following	_
74-25	12587-12595	blurring	_
74-26	12596-12597	(	_
74-27	12598-12599	5	_
74-28	12600-12602	mm	_
74-29	12603-12604	)	_
74-30	12605-12606	;	_
74-31	12607-12610	and	_
74-32	12611-12612	2	_
74-33	12613-12614	)	_
74-34	12615-12617	an	_
74-35	12618-12625	updated	_
74-36	12626-12633	version	_
74-37	12634-12636	of	_
74-38	12637-12647	3dClustSim	_
74-39	12648-12651	was	_
74-40	12652-12655	run	_
74-41	12656-12658	to	_
74-42	12659-12666	account	_
74-43	12667-12670	for	_
74-44	12671-12686	autocorrelation	_
74-45	12687-12692	given	_
74-46	12693-12696	our	_
74-47	12697-12714	voxel/whole-brain	_
74-48	12715-12719	mask	_
74-49	12720-12724	size	_
74-50	12725-12726	,	_
74-51	12727-12733	10,000	_
74-52	12734-12739	Monte	_
74-53	12740-12745	Carlo	_
74-54	12746-12757	simulations	_
74-55	12758-12761	and	_
74-56	12762-12771	two-sided	_
74-57	12772-12784	thresholding	_
74-58	12785-12789	with	_
74-59	12790-12792	an	_
74-60	12793-12800	overall	_
74-61	12801-12806	voxel	_
74-62	12807-12808	p	_
74-63	12809-12820	statistical	_
74-64	12821-12830	threshold	_
74-65	12831-12833	of	_
74-66	12834-12838	0.01	_
74-67	12839-12842	and	_
74-68	12843-12844	a	_
74-69	12845-12854	corrected	_
74-70	12855-12866	clusterwise	_
74-71	12867-12872	alpha	_
74-72	12873-12878	value	_
74-73	12879-12881	of	_
74-74	12882-12886	0.01	_
74-75	12887-12888	.	_

Text=Data smoothness was approximately 6 mm and> 19 neighboring voxels (or> 1216 μL) comprised a significant brain cluster.
75-1	12889-12893	Data	_
75-2	12894-12904	smoothness	_
75-3	12905-12908	was	_
75-4	12909-12922	approximately	_
75-5	12923-12924	6	_
75-6	12925-12927	mm	_
75-7	12928-12931	and	_
75-8	12932-12933	>	_
75-9	12934-12936	19	_
75-10	12937-12948	neighboring	_
75-11	12949-12955	voxels	_
75-12	12956-12957	(	_
75-13	12958-12960	or	_
75-14	12961-12962	>	_
75-15	12963-12967	1216	_
75-16	12968-12970	μL	_
75-17	12971-12972	)	_
75-18	12973-12982	comprised	_
75-19	12983-12984	a	_
75-20	12985-12996	significant	_
75-21	12997-13002	brain	_
75-22	13003-13010	cluster	_
75-23	13011-13012	.	_

